New Indication for Emend

February 1, 2006
Oncology NEWS International, Oncology NEWS International Vol 15 No 2, Volume 15, Issue 2

The FDA has approved Merck & Co.'s Emend (aprepitant) for use with other antiemetic medicines for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.

WHITEHOUSE STATION, New Jersey-The FDA has approved Merck & Co.'s Emend (aprepitant) for use with other antiemetic medicines for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy. Emend was previously approved for use, in combination with other antiemetics, for the prevention of nausea and vomiting caused by initial and repeat courses of highly emetogenic chemotherapy, including high-dose cisplatin. Approval was based on a study comparing a regimen of Emend, ondansetron (Zofran), and dexamethasone on day 1 followed by Emend on days 2 and 3 vs ondansetron/dexamethasone on day 1 followed by ondansetron on days 2 and 3 (N Engl J Med, April 2005).